Eyepoint Pharmaceuticals Inc
$ 17.05
-0.12%
24 Feb - close price
- Market Cap 1,413,178,000 USD
- Current Price $ 17.05
- High / Low $ 17.74 / 16.75
- Stock P/E N/A
- Book Value 2.88
- EPS -3.00
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.49 %
- ROE -0.98 %
- 52 Week High 19.11
- 52 Week Low 3.91
About
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$36.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-03-05 | 2024-11-08 | 2024-08-07 | 2024-05-08 | 2024-03-07 | 2023-11-01 | 2023-08-02 | 2023-05-03 | 2023-03-02 |
| Reported EPS | -0.85 | -0.85 | -0.65 | -0.64 | -0.54 | -0.58 | -0.55 | -0.33 | -0.33 | -0.61 | -0.56 | -1.16 |
| Estimated EPS | -0.77 | -0.81 | -0.41 | -0.4765 | -0.55 | -0.52 | -0.42 | -0.49 | -0.51 | 0.6 | -0.68 | -0.61 |
| Surprise | -0.08 | -0.04 | -0.24 | -0.1635 | 0.01 | -0.06 | -0.13 | 0.16 | 0.18 | -1.21 | 0.12 | -0.55 |
| Surprise Percentage | -10.3896% | -4.9383% | -58.5366% | -34.3127% | 1.8182% | -11.5385% | -30.9524% | 32.6531% | 35.2941% | -201.6667% | 17.6471% | -90.1639% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.78 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EYPT
2026-02-24 11:53:08
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) announced its management will participate in several upcoming investor conferences in March 2026, including the TD Cowen Health Care Conference, Barclays Global Healthcare Conference, Jefferies Biotech on the Beach Summit, and RBC Capital Markets Virtual Ophthalmology Conference. The company will discuss its innovative therapeutics for serious retinal diseases, including its lead product candidate DURAVYU™. Webcasts of presentations will be available on EyePoint's investor relations website.
2026-02-20 09:28:40
Aberdeen Group plc reduced its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 22.7% in the third quarter of 2025, selling 234,399 shares and retaining 796,802 shares valued at $11.346 million. This reduction leaves Aberdeen Group plc owning approximately 1.16% of the company. Despite this sale, analysts remain largely bullish on EYPT, with an average rating of "Buy" and an average price target of $29.25, though one analyst has a "sell" rating.
2026-02-19 18:18:12
This article details recent leadership changes across the pharmaceutical, biotech, and medical marketing industries, including new hires, executive promotions, and board appointments. Key moves include Belén Garijo becoming Sanofi's CEO, Mike Campbell joining EyePoint as chief commercial officer, and Jag Dosanjh's elevation at AbbVie. The piece also notes significant departures from Sanofi and the Department of Health and Human Services.
2026-02-18 22:57:04
Eyepoint Pharmaceuticals (NASDAQ:EYPT) saw its shares drop 4.4% during mid-day trading with increased volume. Despite the dip, analyst sentiment remains largely positive, with a consensus "Buy" rating and an average price target of $29.25, supported by recent upgrades from RBC, TD Cowen, and Cantor Fitzgerald. However, one insider recently sold a significant number of shares, while institutional ownership is high.
2026-02-18 16:57:04
EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy for its investigational treatment, DURAVYU, currently in Phase 3 development. Campbell brings over 30 years of ophthalmology commercial experience, including a key role in the launch of Lucentis. His appointment comes as EyePoint anticipates topline data from its Phase 3 program in wet AMD in mid-2026.
2026-02-18 16:57:04
EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to spearhead the commercial strategy for DURAVYU, its Phase 3 candidate for wet age-related macular degeneration and diabetic macular edema. Campbell's extensive experience in ophthalmology product launches is expected to be a significant asset, though EyePoint still faces challenges with high cash burn and dependence on external capital to fund DURAVYU's development and commercialization. The success of DURAVYU remains central to EyePoint's investment narrative, with diverse analyst forecasts highlighting both potential upside and considerable risks for investors.
